AimsThe glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exenatide once weekly (ExQW) and liraglutide once daily (QD) are indicated to improve glycaemic control in patients with type 2 diabetes. Although glycaemic control with ExQW versus liraglutide QD 1.8 mg has been directly compared...
subcutaneous (under the skin) injection in the abdomen, thigh or upper arm. Products are available as injector pens and can be used by the patient or a caregiver at home, after instruction. These medicines should not be used together or with other GLP-1 or GIP / GLP-1 receptor agonists....
analysisnetwork meta‐analysisreceptor agoniststype 2 diabetesAims The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exenatide once weekly (ExQW) and liraglutide once daily (QD) are indicated to improve glycaemic control in patients with type 2 diabetes. Although glycaemic control with ExQW...
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardio- vascular and pancreatic outcomes. Cardiovasc Diabetol. 2017;16(1):31.ZHANG Z, CHEN X, LU P, et al. Incretin-based agents in type 2 diabet- ic ...
Padhiar A, Thompson JC, Eaton JN, Hawkins NS, Norrbacka K, Reaney M, et al. A network meta-analysis to compare once weekly dulaglutide versus other GLP-1 receptor agonists in patients with type 2 diabetes. European Association for the Study of Diabetes Annual Meeting 2014....